Us Congress Senate Bill SB1941

Us Congress 2025-2026 Regular Session

• Introduced: 6/4/25
• Refer: 6/4/25

Caption

Cure Hepatitis C Act of 2025

Impact

One of the notable impacts of SB1941 is the authorization of significant federal funding, amounting to approximately $5.5 billion for fiscal year 2025. This funding is earmarked for implementing public health activities such as grants to states aimed at enhancing outreach programs. Moreover, the bill aims to eliminate cost-sharing for direct acting antiviral drugs for hepatitis C, which is expected to improve treatment adherence and reduce financial barriers for patients.

Summary

SB1941, titled the 'Cure Hepatitis C Act of 2025', aims to implement comprehensive measures for the elimination of the hepatitis C virus in the United States. The bill mandates the Secretary of Health and Human Services to execute a range of activities focused on increasing access to screening, diagnosis, and treatment for hepatitis C, particularly targeting populations at an increased risk of infection. This includes provisions for directly funding states and local organizations to elevate public health initiatives that encourage awareness and treatment access.

Contention

Discussion around SB1941 has highlighted concerns about equitable access to treatments and the distribution of funds among states. Critics have raised questions about the effectiveness of a centralized federal approach compared to state-led initiatives, particularly in ensuring that marginalized groups receive the necessary treatments. Furthermore, there are apprehensions about the administrative burdens that may arise from managing a new subscription model for drug procurement among suppliers.